Form: 8-K

Current report filing

February 3, 2005

Exhibit 99.1

 

RESMED INC ANNOUNCES RECORD FINANCIAL RESULTS FOR

QUARTER AND SIX MONTHS ENDED DECEMBER 31, 2004

 

SAN DIEGO, California, February 3, 2005 - ResMed Inc (NYSE: RMD) today announced record revenue and income results for the quarter ended December 31, 2004. Revenue for the quarter was $103.9 million, a 26% increase over the quarter ended December 31, 2003. For the December 31, 2004 quarter, income from operations and net income, both excluding the impact of restructuring expenses and donation to foundation described below, were $27.1 million and $18.3 million, an increase of 36% and 27%, respectively. Diluted earnings per share, excluding the impact of restructuring expenses and donation to foundation, for the quarter ended December 31, 2004 were $0.52, an increase of 27%, compared to the December 2003 quarter. Net income for the current quarter was $17.4 million or $0.49 per diluted share including after-tax restructuring expenses of $0.6 million. Gross margin was 66%.

 

Selling, general and administration (SG&A) costs for the quarter were $33.5 million, an increase of $7.7 million or 30% over the same period in fiscal 2003. The increase in gross SG&A related primarily to an increase in selling and administration personnel to meet expanding opportunities in the sleep-disordered breathing market. SG&A expenditure as a percentage of revenue was 32% in the December quarter, compared to 31% for the same period in fiscal 2004.

 

Research and development expenditure, at approximately 8% of revenues, increased 16% during the three months ended December 31, 2004 to $7.8 million from $6.8 million in the quarter ended December 31, 2003. The increase reflects ResMed’s continuing commitment to clinical research and product development, as well as a stronger Australian dollar. ResMed intends to continue to spend approximately 8% of revenues on R&D during the rest of fiscal year 2005.

 

For the six months ended December 31, 2004 revenues were $191.6 million, an increase of 23% over the $155.2 million for the six months ended December 31, 2003. For the six months ended December 31, 2004, income from operations and net income, both excluding the impact of restructuring expenses and donation to foundation described below were $50.0 million and $33.4 million, an increase of 29% and 25% respectively. Net income for the six months ended December 31, 2004 was $31.3 million or $0.89 per diluted share including after tax restructuring expenses of $1.8 million.

 

Restructuring expenses incurred during the quarter ended December 31, 2004 of $1.0 million ($0.6 million net of tax) consisted of expenses associated with the previously-announced integration of the Company’s German operations.

 

During the quarter, we committed to donate $500,000 to the ResMed Foundations. The foundations were established to promote awareness of and research into the serious medical consequences of untreated SDB.

 

With the financial information included in this press release, the Company is providing a tabular reconciliation of GAAP operating income and GAAP net income with operating income, and net income, excluding the impact of restructuring expenses and excluding the impact of the donation to the foundation.

 

Inventory at $64.9 million, increased by $3.8 million compared to September 2004 levels. Accounts receivable days sales outstanding, at 66 days, improved compared to the September 2004 quarter of 70 days.

 

Peter C. Farrell PhD, Chairman and Chief Executive Officer, commented, “These robust financial results for the second quarter of fiscal 2005 reflect ResMed’s continuing sales and profit growth. Domestic sales increased by 27% over the December 2004 quarter to $52.3 million, reflecting an outstanding effort from our sales team and strong demand for our new Mirage Swift patient interface. International sales increased by 25% over the December 2004 quarter, to $51.6 million, reflecting


growth in all our major markets as well as a stronger Euro. In addition, we expanded our international operations with the acquisition of Resprecare, our exclusive distributor in the Netherlands, and we continue to evaluate additional opportunities for international expansion. Our operating cash flow for the December quarter was a very robust $22.3 million.”

 

“We achieved significant growth in the first half of fiscal 2005. In the current quarter, we are focused on growing above the tremendous financial results we delivered in the third quarter of last year. We reiterate our expectation for market growth of 15 to 20 percent over the next 12 to 18 months,” Dr. Farrell further commented. “Even as we continue to grow in our key markets throughout the world, most remain under-penetrated, and patients remain underserved. To best address these global opportunities, we are enhancing our leadership structure to support continued, encouraging growth. Keith Serzen has been promoted to Chief Operating Officer, Americas and Adrian Smith has assumed the additional responsibility of Acting Chief Operating Officer, Europe. These modifications to the geographic leadership structure support our core, customer-focused values while providing strengthened leadership.”

 

ResMed is a leading developer, manufacturer, and marketer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing, selling a comprehensive range of products in over 60 countries.

 

ResMed will host a conference call at 1:30 p.m. Pacific Standard Time (PST) today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed’s Web site at www.resmed.com or by dialing (888) 396-2386 (domestic) or +1 (617) 847-8712 (international) and entering conference I.D. No. 82312541. Please allow extra time prior to the call to visit the Web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing (888) 286-8010 (domestic) and +1 (617) 801-6888 (international) and entering conference I.D. No. 51571140.

 

Further information can be obtained by contacting Hillary Theakston at ResMed Inc. San Diego (858) 746-2610; Brett Sandercock ResMed Limited Sydney on +61 (2) 9886-5406; or by visiting the Company’s multilingual Web site at www.resmed.com.

 

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company’s future revenue, earnings or expenses, new product development and new markets for the Company’s products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the US Securities & Exchange Commission. Those reports are available on the Company’s Web site.

 

- More -


RESMED INC. AND SUBSIDIARIES

 

Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)

 

     Three Months Ended
December 31,


    Six Months Ended
December 31,


 
     2004

    2003

    2004

    2003

 

Net revenue

   $ 103,893     $ 82,292     $ 191,626     $ 155,170  

Cost of sales

     35,515       29,868       66,837       55,588  
    


 


 


 


Gross profit

     68,378       52,424       124,789       99,582  
    


 


 


 


Operating expenses:

                                

Selling, general and administrative

     33,469       25,765       60,133       47,952  

Donation to Foundation

     500       500       500       500  

Research and development

     7,842       6,766       14,661       12,783  

Restructuring expenses

     958       0       2,926       0  
    


 


 


 


Total operating expenses

     42,769       33,031       78,220       61,235  
    


 


 


 


Income from operations

     25,609       19,393       46,569       38,347  
    


 


 


 


Other income (expenses), net

                                

Interest income (expense), net

     (159 )     (368 )     (480 )     (762 )

Other, net

     679       1,883       710       1,231  
    


 


 


 


Total other income (expenses), net

     520       1,515       230       469  
    


 


 


 


Income before income taxes

     26,129       20,908       46,799       38,816  

Income taxes

     8,725       6,757       15,469       12,416  
    


 


 


 


Net income

     17,404     $ 14,151     $ 31,330     $ 26,400  
    


 


 


 


Basic earnings per share

   $ 0.51     $ 0.42     $ 0.92     $ 0.78  

Diluted earnings per share(1)

   $ 0.49     $ 0.40     $ 0.89     $ 0.75  

Diluted earnings per share excluding the impact of of restructuring expenses and donation(2)

   $ 0.52     $ 0.41     $ 0.95     $ 0.76  

Basic shares outstanding

     34,012       33,663       33,951       33,658  

Diluted shares outstanding

     37,102       35,044       37,115       35,069  

(1) Diluted earnings per share has been calculated after adjusting the numerator (net income) by $821,000 and $1,642,000 for the three months ended December 31 and six months ended December 31, respectively, for the effect of assumed conversion of our convertible subordinated notes.
(2) See reconciliation of non-GAAP financial measures in table at end of press release.

 

- More -


RESMED INC. AND SUBSIDIARIES

 

Consolidated Balance Sheets (Unaudited)

(In US$ thousands except share and per share data)

 

     December 31,
2004


    June 30,
2004


 

ASSETS

                

Current assets:

                

Cash and cash equivalents

   $ 143,068     $ 128,907  

Marketable securities - available for sale

     21,976       12,021  

Accounts receivable, net

     76,861       67,242  

Inventories

     64,854       55,797  

Deferred income taxes

     9,238       7,041  

Prepaid expenses and other current assets

     7,249       6,821  
    


 


Total current assets

     323,246       277,829  
    


 


Property, plant and equipment, net of accumulated depreciation

     166,399       147,268  

Goodwill and Intangibles

     125,335       110,889  

Other assets

     9,511       8,173  
    


 


Total assets

   $ 624,491     $ 544,159  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

   $ 17,820     $ 18,574  

Accrued expenses

     28,134       22,591  

Income taxes payable

     14,895       8,470  

Deferred revenue

     11,337       8,759  

Current portion of deferred profit on sale and leaseback

     1,116       2,197  
    


 


Total current liabilities

     73,302       60,591  
    


 


Non Current Liabilities:

                

Deferred Revenue

     10,540       8,819  

Convertible subordinated notes

     113,250       113,250  
    


 


Total non-current liabilities

     123,790       122,069  
    


 


Total liabilities

     197,092     $ 182,660  
    


 


Stockholders’ equity:

                

Common Stock

     136       135  

Additional paid-in capital

     143,051       132,875  

Retained earnings

     248,986       217,656  

Treasury stock

     (41,405 )     (30,440 )

Accumulated other comprehensive income

     76,631       41,273  
    


 


Total stockholders’ equity

     427,399       361,499  
    


 


Total liabilities and stockholders’ equity

   $ 624,491     $ 544,159  
    


 



Reconciliation of Non-GAAP Financial Measures (Unaudited)

(Dollars in thousands except per share amounts)

 

In managing its business, ResMed makes use of certain non-GAAP financial measures in evaluating the Company’s results of operations. The measure, “operating income, excluding the impact of restructuring expenses and donation to foundation,” is reconciled with GAAP operating income in the table below:

 

     Three Months Ended
December 31,


   Six Months Ended
December 31,


     2004

   2003

   2004

   2003

GAAP operating income

     25,609      19,393      46,569      38,347

Restructuring expenses

     958      —        2,926      —  

Donation to Foundation

     500      500      500      500

Operating income, excluding the impact of restructuring expenses and donation to foundation

     27,067      19,893      49,995      38,847
The measure, “net income, excluding the impact of restructuring expenses and donation to foundation,” is reconciled with GAAP net income in the table below:
     Three Months Ended
December 30,


   Six Months Ended
December 30,


     2004

   2003

   2004

   2003

GAAP net income

     17,404      14,151      31,330      26,400

Restructuring expenses, net of tax

     613      —        1,805      —  

Donation to foundation, net of tax

     310      310      310      310

Net income, excluding the impact of restructuring expenses and donation to foundation

     18,327      14,461      33,445      26,710

Diluted shares outstanding

     37,102      35,044      37,115      35,069

Diluted earnings per share, excluding the impact of restructuring expenses and donation to foundation Operating income, excluding the impact of restructuring expenses

   $ 0.52    $ 0.41    $ 0.95    $ 0.76

 

ResMed believes that presenting diluted earnings per share, excluding the impact of restructuring expenses and donation to foundation, is an additional measure of performance that investors can use to compare operating results between reporting periods. Management of the Company uses this information in evaluating the Company’s results of operations and believes that this information also provides investors better insight in evaluating the Company’s earnings performance from core operations. The events giving rise to these restructuring expenses and donation to foundation are not associated with the Company’s normal operating business and are expected to result in future market opportunities, cost savings, and other benefits.